Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [
Go to this article.]
Figure 2CCL20 expression at the tumor site induces the regression of CT26 but not B16 tumors. (A–D) Graphs showing tumor growth (A and C) and survival (B and D) of mice injected with 2 × 10
6 CT26 (A and B) or 5 × 10
4 B16 (C and D) parental tumor cells (parent) or tumor cells transduced with CCL20 or a mock vector. *
P < 0.05 between CCL20 and control groups. In B, survival rate was significantly higher (
P < 0.0001) in CCL20 versus control groups. The results shown are the mean of five separate experiments in A and B and two separate experiments in C and D.
